ArticleHaematologica2021
Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia.
Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune thrombocytopenia in patients with systemic lupus erythematosus.Clinical rheumatology · 2025Pooled it
- Safety and efficacy of daratumumab in immune thrombocytopenia.Blood advances · 2026Trial
- Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.BMJ (Clinical research ed.) · 2025Trial
- Single low-dose daratumumab enhances rituximab efficacy for sustained remission in treatment-refractory autoimmune cytopenias.Annals of hematology · 2026Article
- Thrombocytopenia: from physiological homeostasis imbalance to mechanism-driven precision diagnosis and therapy.Frontiers in immunology · 2026Review
- Daratumumab in relapsed or refractory immune thrombocytopenic purpura.Blood science (Baltimore, Md.) · 2025Article
- Daratumumab and Romiplostim Combined Therapy for a Long-Standing Refractory Primary Immune Thrombocytopenia - Case Report.ImmunoTargets and therapy · 2025Article
- Effective treatment with daratumumab in post-HSCT refractory immune-mediated cytopenias: a case report and literature review.Frontiers in immunology · 2025Review
- Autoimmune haemolytic anaemias.Nature reviews. Disease primers · 2024Review
- Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation.Kidney international reports · 2024Article
- [Chinese expert consensus on the diagnosis and treatment of Evans syndrome (2024)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.Blood advances · 2024Article
- Time for newer approach in age-old AIHA: Daratumumab?The Lancet regional health. Southeast Asia · 2024Article
- Time for newer approach in age-old AIHA.The Lancet regional health. Southeast Asia · 2024Article
- B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses.Life science alliance · 2023Article
- Article
- Combination regimens containing daratumumab for initial diagnosed acquired thrombotic thrombocytopenic purpura.Journal of thrombosis and thrombolysis · 2023Article
- Rituximab resistance in ITP and beyond.Frontiers in immunology · 2023Review
- Novel Therapies to Address Unmet Needs in ITP.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Targeted treatment of autoimmune cytopenias in primary immunodeficiencies.Frontiers in immunology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.